PL2362218T3 - Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej - Google Patents
Sposoby kontroli skuteczności inhibitorów transferazy farnezylowejInfo
- Publication number
- PL2362218T3 PL2362218T3 PL11158145T PL11158145T PL2362218T3 PL 2362218 T3 PL2362218 T3 PL 2362218T3 PL 11158145 T PL11158145 T PL 11158145T PL 11158145 T PL11158145 T PL 11158145T PL 2362218 T3 PL2362218 T3 PL 2362218T3
- Authority
- PL
- Poland
- Prior art keywords
- efficacy
- monitoring
- methods
- farnesyltransferase inhibitors
- farnesyltransferase
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62520404P | 2004-11-05 | 2004-11-05 | |
| US70807505P | 2005-08-12 | 2005-08-12 | |
| EP05851365A EP1815247B1 (en) | 2004-11-05 | 2005-11-02 | Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof |
| EP11158145.0A EP2362218B1 (en) | 2004-11-05 | 2005-11-02 | Methods of monitoring the efficacy of farnesyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2362218T3 true PL2362218T3 (pl) | 2015-02-27 |
Family
ID=35840451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11158145T PL2362218T3 (pl) | 2004-11-05 | 2005-11-02 | Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej |
| PL05851365T PL1815247T3 (pl) | 2004-11-05 | 2005-11-02 | Terapeutyczne zastosowanie inhibitorów transferazy farnezylowej i metody kontroli ich skuteczności |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05851365T PL1815247T3 (pl) | 2004-11-05 | 2005-11-02 | Terapeutyczne zastosowanie inhibitorów transferazy farnezylowej i metody kontroli ich skuteczności |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20060111398A1 (pl) |
| EP (2) | EP1815247B1 (pl) |
| DK (2) | DK2362218T3 (pl) |
| ES (2) | ES2522830T3 (pl) |
| HR (1) | HRP20130399T1 (pl) |
| ME (1) | ME01509B (pl) |
| PL (2) | PL2362218T3 (pl) |
| PT (2) | PT2362218E (pl) |
| RS (1) | RS52741B (pl) |
| SI (1) | SI2362218T1 (pl) |
| WO (1) | WO2006052718A2 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089496A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| WO2010057006A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| BRPI0921113A2 (pt) * | 2008-11-13 | 2016-02-16 | Link Medicine Corp | tratamento de proteinopatias usando um inibidor de farnesil transferase. |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| SG11201502935VA (en) | 2012-10-16 | 2015-09-29 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
| PT2909192T (pt) | 2012-10-16 | 2017-08-04 | Janssen Pharmaceutica Nv | Moduladores de ror-gama-t quinolinilo ligados por metileno |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｒｏｒγｔのアルキル結合キノリニルモジュレーター |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| EP3057422B1 (en) | 2013-10-15 | 2019-05-15 | Janssen Pharmaceutica NV | Quinolinyl modulators of ror(gamma)t |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| EP3164717B1 (en) * | 2014-07-02 | 2019-08-28 | Bionomics Limited | Predictive biomarkers |
| WO2016090107A2 (en) * | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| KR102514971B1 (ko) | 2015-04-21 | 2023-03-27 | 아이거 바이오파마슈티컬스 인코포레이티드 | 로나파르닙 및 리토나버를 포함하는 약제 조성물 |
| PL3640345T3 (pl) | 2015-08-17 | 2022-02-07 | Kura Oncology, Inc. | Sposoby leczenia pacjentów z nowotworem z użyciem inhibitorów farnezylotransferazy |
| CN105510187B (zh) * | 2016-01-28 | 2018-01-23 | 青岛啤酒股份有限公司 | 用于啤酒糖化过程中快速判定麦汁发酵度的方法 |
| ES2863730T3 (es) | 2016-11-03 | 2021-10-11 | Kura Oncology Inc | Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer |
| US20230192631A1 (en) * | 2020-04-16 | 2023-06-22 | Hoffmann-La Roche Inc. | Biphenyl Derivatives |
| US20250049837A1 (en) * | 2023-01-09 | 2025-02-13 | Unity Health Toronto | Microrna-based particle for the treatment of dysregulated immune response |
| WO2025101692A1 (en) * | 2023-11-10 | 2025-05-15 | The Children's Medical Center Corporation | Methods and compositions for the treatment of vascular anomalies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117432A (en) | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| EP1162201B1 (en) | 1995-12-08 | 2006-03-29 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| CN1095845C (zh) | 1996-12-20 | 2002-12-11 | "塔比法尔"有限责任公司 | 制取冻干的1β,10β－环氧－13－二甲基氨基－愈创－3(4)－烯－6,12－内酯盐酸盐的方法和装置 |
| TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| GB2323783A (en) | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
| US6177432B1 (en) | 1997-04-25 | 2001-01-23 | Janssen-Cilag S.A. | Farnesyltransferase inhibiting quinazolinones |
| BR9908568B1 (pt) | 1998-03-05 | 2013-09-03 | sistema de comunicações, método de comunicação de um sinal de vídeo e método de estabelecimento de um sistema de comunicações. | |
| US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
| AU5086499A (en) | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| HK1039123A1 (zh) | 1998-08-27 | 2002-04-12 | 辉瑞产品公司 | 用作抗癌剂的炔基取代的喹啉-2-酮衍生物 |
| ATE289602T1 (de) | 1998-08-27 | 2005-03-15 | Pfizer Prod Inc | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| US6458800B1 (en) | 1998-12-23 | 2002-10-01 | Janssen Pharmaceutica N.V. | 1,2-annelated quinoline derivatives |
| GB0023915D0 (en) | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
| EP1339407B1 (en) | 2000-11-28 | 2006-04-19 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
| US20040157773A1 (en) | 2001-04-25 | 2004-08-12 | End David William | Farnesyl protein transferase inhibitors for treating cachexia |
| BR0316231A (pt) * | 2002-11-12 | 2005-10-04 | Becton Dickinson Co | Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit |
-
2005
- 2005-11-02 PL PL11158145T patent/PL2362218T3/pl unknown
- 2005-11-02 HR HRP20130399TT patent/HRP20130399T1/hr unknown
- 2005-11-02 RS RS20130146A patent/RS52741B/sr unknown
- 2005-11-02 EP EP05851365A patent/EP1815247B1/en not_active Expired - Lifetime
- 2005-11-02 EP EP11158145.0A patent/EP2362218B1/en not_active Expired - Lifetime
- 2005-11-02 WO PCT/US2005/039948 patent/WO2006052718A2/en not_active Ceased
- 2005-11-02 PT PT111581450T patent/PT2362218E/pt unknown
- 2005-11-02 ME MEP-2013-46A patent/ME01509B/me unknown
- 2005-11-02 DK DK11158145.0T patent/DK2362218T3/en active
- 2005-11-02 ES ES11158145.0T patent/ES2522830T3/es not_active Expired - Lifetime
- 2005-11-02 DK DK05851365.6T patent/DK1815247T3/da active
- 2005-11-02 PT PT58513656T patent/PT1815247E/pt unknown
- 2005-11-02 PL PL05851365T patent/PL1815247T3/pl unknown
- 2005-11-02 SI SI200531911T patent/SI2362218T1/sl unknown
- 2005-11-02 US US11/265,445 patent/US20060111398A1/en not_active Abandoned
- 2005-11-02 ES ES05851365T patent/ES2403060T3/es not_active Expired - Lifetime
-
2009
- 2009-02-02 US US12/363,810 patent/US20110195419A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,200 patent/US20120196766A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110195419A1 (en) | 2011-08-11 |
| WO2006052718A2 (en) | 2006-05-18 |
| RS52741B (sr) | 2013-08-30 |
| PT1815247E (pt) | 2013-04-23 |
| HRP20130399T1 (hr) | 2013-06-30 |
| EP2362218A2 (en) | 2011-08-31 |
| EP1815247B1 (en) | 2013-02-20 |
| EP2362218A3 (en) | 2011-10-26 |
| ES2522830T3 (es) | 2014-11-18 |
| HK1110651A1 (en) | 2008-07-18 |
| WO2006052718A8 (en) | 2007-02-08 |
| DK1815247T3 (da) | 2013-03-11 |
| ES2403060T3 (es) | 2013-05-13 |
| SI2362218T1 (sl) | 2014-12-31 |
| US20120196766A1 (en) | 2012-08-02 |
| PT2362218E (pt) | 2014-12-04 |
| WO2006052718A3 (en) | 2007-06-28 |
| PL1815247T3 (pl) | 2013-08-30 |
| DK2362218T3 (en) | 2014-11-17 |
| ME01509B (me) | 2014-04-20 |
| EP2362218B1 (en) | 2014-08-27 |
| US20060111398A1 (en) | 2006-05-25 |
| EP1815247A2 (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2362218T3 (pl) | Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej | |
| AP2870A (en) | Odcase inhibitors for the treatment of malaria | |
| ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
| IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
| PL1745041T3 (pl) | Inhibitory chinoksalinowe szlaku sygnałowego hedgehog | |
| IL190968A0 (en) | Inhibitors of akt activity | |
| EP1968568A4 (en) | HEMMER OF NUTS ACTIVITY | |
| IL187690A0 (en) | Inhibitors of akt activity | |
| IL179398A0 (en) | Dpp-ib inhibitors | |
| IL189976A0 (en) | Methods of modulating neurotrophin-mediated activity | |
| IL190913A0 (en) | Methods for the treatment of hyperhidrosis | |
| IL185757A0 (en) | Methods of decreasing calcifcation | |
| PL1725528T3 (pl) | Sulfonylopirole jako inhibitory HDAC | |
| GB0400290D0 (en) | dUTPase inhibitors | |
| IL179333A0 (en) | Monitoring the efficacy of fluid resuscitation | |
| GB0421355D0 (en) | Inhibitors | |
| DK2392335T3 (en) | Use of 24-norUDCA | |
| EP1789055A4 (en) | INHIBITORS OF THIAZOLOPYRIDINE KINASE | |
| EP1948185A4 (en) | INHIBITORS OF AKT ACTIVITY | |
| GB0421356D0 (en) | Inhibitors | |
| GB0504209D0 (en) | New use of PDE7 inhibitors | |
| GB0318913D0 (en) | Apoptosis inhibitors | |
| GB0516967D0 (en) | Inhibitors | |
| SI1815247T1 (sl) | Terapevtska uporaba inhibitorjev farneziltransferaze in postopki nadziranja njihove učinkovitosti | |
| ZA200709762B (en) | Inhibitors of Akt activity |